(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 26.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Opus Genetics's revenue in 2026 is $14,196,000.On average, 12 Wall Street analysts forecast IRD's revenue for 2026 to be $1,221,557,954, with the lowest IRD revenue forecast at $557,808,513, and the highest IRD revenue forecast at $2,241,194,918. On average, 11 Wall Street analysts forecast IRD's revenue for 2027 to be $1,362,646,510, with the lowest IRD revenue forecast at $557,808,513, and the highest IRD revenue forecast at $3,205,406,775.
In 2028, IRD is forecast to generate $2,271,717,858 in revenue, with the lowest revenue forecast at $766,986,705 and the highest revenue forecast at $4,638,348,542.